Teniposide
Teniposide Basic information
- Product Name:
- Teniposide
- Synonyms:
-
- (5R,5aα)-5α,8,8aβ,9β-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4-O,6-O-[(R)-2-thienylmethylene]-β-D-glucopyranosyl]oxy]furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
- 4'-Demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene β-D-glucopyranoside)
- 4’-Demethylepipodophyllotoxin9-(4,6-o-2-thenylidene-
- 4'-Demethylepipodophyllotoxin thenylidene glucoside
- Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-o-2-thienylidene-.beta.-D-glucopyranoside)
- Furo[3',4':6,7]naphtho[2,3-D]-1,3-dioxol-6(5ah)-one, 5,8,8A,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-o-(2-thienylmethylene)-.beta.-D-glucopyranosyl]oxy]-, [5R-(5.alpha.,5A.beta.,8A.alpha.,9.beta.)]-
- (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-diMethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1,3(7),8-trien-12-one
- Teniposide(VuMon)
- CAS:
- 29767-20-2
- MF:
- C32H32O13S
- MW:
- 656.65
- EINECS:
- 249-831-2
- Product Categories:
-
- Carbohydrates & Derivatives
- Chiral Reagents
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Isotope Labelled Compounds
- Active Pharmaceutical Ingredients
- VUMON
- API
- Inhibitors
- 29767-20-2
- Mol File:
- 29767-20-2.mol
Teniposide Chemical Properties
- Melting point:
- 244-247°C
- alpha
- D20 -107° (9:1 chloroform/methanol)
- Boiling point:
- 650.86°C (rough estimate)
- Density
- 1.2568 (rough estimate)
- refractive index
- 1.5530 (estimate)
- storage temp.
- -20°C
- solubility
- DMSO: soluble10mg/mL, clear
- pka
- 10.13(at 25℃)
- form
- powder
- color
- white to beige
- optical activity
- [α]/D -100 to -115°, c = 1 in chloroform/methanol (9:1)
- λmax
- 283nm(MeOH)(lit.)
- Merck
- 14,9145
- Stability:
- Hygroscopic
- CAS DataBase Reference
- 29767-20-2(CAS DataBase Reference)
- IARC
- 2A (Vol. 76) 2000
Safety Information
- Hazard Codes
- Xi,T
- Risk Statements
- 36/37/38-45
- Safety Statements
- 26-36-45-53
- RIDADR
- UN 2811 6.1 / PGIII
- WGK Germany
- 3
- RTECS
- KC0180000
- HS Code
- 29349990
- Hazardous Substances Data
- 29767-20-2(Hazardous Substances Data)
- Toxicity
- LD50 intraperitoneal in mouse: 29570ug/kg
Teniposide Usage And Synthesis
Chemical Properties
White Solid
Originator
Vehem,Sandoz,France,1976
Uses
Teniposide is a podophyllotoxin derivative that causes dose-dependent single- and double-stranded breaks in DNA by inhibiting topoisomerase II. Its cytostatic effects are related to its ability to stabilize the DNA-topoisomerase II complex during DNA replication, inducing DNA damage and cellular apoptosis. Teniposide has been widely used in the treatment of various cancers including, small cell lung cancer, malignant lymphoma, breast cancer, oral squamous cell carcinoma, and acute lymphoblastic leukemia.
Uses
A labelled semi-synthetic derivative of Podophyllotoxin. Antineoplastic.
Uses
A semi-synthetic derivative of Podophyllotoxin. Antineoplastic.
Indications
Teniposide (VM-26, Vumon) is closely related to etoposide in structure, mechanisms of action and resistance, and adverse effects. It is more lipophilic and approximately threefold more potent than etoposide. Its major uses have been in pediatric cancers, particularly in acute lymphoblastic leukemias.
Definition
ChEBI: A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.
Manufacturing Process
10 ml of pure thiophene-2-aldehyde and 0.25 g of anhydrous zinc chloride are American Home Products Corporation; British Patent 1,022,642; March 16,
1966
American Home Products Corporation; British Patent 1,022,645; March 16,
1966
Bell, S.C.; British Patent 1,057,492; February 1, 1967; assigned to American
Home Products Corporation
brand name
Vumon (Bristol-Myers Squibb).
Therapeutic Function
Antineoplastic
General Description
Teniposide is available in 50-mg ampules with Cremophor ELfor IV administration in the treatment of acute lymphoblasticleukemia (ALL). The agent is more potent as an inhibitor oftopoisomerase II. The pharmacokinetics of teniposide issimilar to that of etoposide; however, the more lipophilic teniposideis more highly protein bound (99%) and less isexcreted unchanged in the urine (10%–20%). There is alsogreater overall metabolism of teniposide; however, CYP3A4-mediated conversion to the active catechol is slower comparedwith etoposide. Elimination occurs primarily in the urine witha terminal elimination half-life of 5 hours.
Biochem/physiol Actions
Teniposide (VM-26) is a Topoisomerase II inhibitor with antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, inducing breaks in double stranded DNA and preventing repair.
Clinical Use
Teniposide is used in combination with other agents for the treatment of refractory childhood acute lymphoblastic leukemia.
Safety Profile
Poison by intraperitoneal and subcutaneous routes. An experimental teratogen. Human systemic effects by ingestion and intravenous route: anorexia, nausea or vomiting, leukopenia, agranulocytosis and aplastic anemia of the blood, bone marrow changes, and hair changes. Experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of SOx.
Synthesis
Teniposide, [5R-(5|á,5a|?,8a|á,9|?)]-9-[4,6-O-(2-thienylmethylene)-|?-D-glucopyranosyl)oxy]- 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3,4: 6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one (30.4.9), is basically synthesized by an analogous scheme from 4-benzyloxy-4-desmethylepipodophyllotoxin (30.4.6), which is esterified by 2,3,4,6- tetra-O-acetyl-|?-D-glucose in the presence of boron trifluoride etherate, giving a glycoside 30.4.7. The acetyl and benzyloxycarbonyl protecting groups in this molecule are removed by succesive use of zinc acetate and sodium methoxide, and then by subsequent hydrogen reduction, which forms the diol 30.4.8. The resulting diol is then transformed into the corresponding acetal 2-formylthiophene, which is the desired teniposide (30.4.9) .
storage
Store at -20°C
TeniposideSupplier
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 021-67121386
- Sales-CN@TCIchemicals.com
- Tel
- 1-(800)-881-8210
- inquiries@lgmpharma.com
Teniposide(29767-20-2)Related Product Information
- Podophyllotoxin
- CHLOROPHOSPHONAZO III
- Centchroman
- Ethylparaben
- Methylparaben
- Ethyl 4-hydroxybenzoate,sodium salt
- Sodium methylparaben
- 4'-demethylepipodophyllotoxin-9 beta-glucopyranoside
- MATAIRESINOL
- 3,3-Diphenylpropionic acid
- 3,5-DIMETHOXYPHENYLPROPIONIC ACID
- 4'-Demethylepipodophyllotoxin
- 7-HYDROXY-1,2,3,4-TETRAHYDRO-NAPHTHALENE-2-CARBOXYLIC ACID
- 2-NAPHTHALENECARBOXYLIC ACID, 1,2,3,4-TETRAHYDRO-6-HYDROXY-
- 6-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALENE-2-CARBOXYLIC ACID
- 3,3-Diphenylpropionic Acid Ethyl Ester
- (R)-4-(4-Methoxybenzyloxy)-1,2-butanediol
- (-)-HYDROXYMATAIRESINOL